Group 1 - The company, Mediwalcan (02159), announced that on January 20, 2026, its subsidiary signed a non-binding memorandum of understanding with a potential seller regarding the possible acquisition of 100% equity in Hong Kong Huanyu Yicheng Intelligent Technology Development Limited and its subsidiaries, collectively referred to as the "Target Group" [1] - The Target Group primarily provides artificial intelligence technology to global pharmaceutical and medical device companies, innovating pharmaceutical research and physician training through its specialized AI medical models [1] - The Target Group also utilizes its core Web3 blockchain technology to ensure the authenticity, security, and traceability of data [1]

Core Viewpoint - The company, Mediwake (02159), announced a non-binding memorandum of understanding regarding the potential acquisition of 100% equity in Hong Kong Huanyu Medical Technology Development Co., Ltd. and its subsidiaries, referred to as the "Target Group" [1] Group 1: Acquisition Details - The memorandum was signed on January 20, 2026, between the company's subsidiary and a potential seller [1] - The Target Group primarily provides artificial intelligence technology to global pharmaceutical and medical device companies [1] Group 2: Technology and Solutions - The Target Group aims to innovate pharmaceutical research and physician training through its specialized AI medical models [1] - It utilizes Web3 core blockchain technology to ensure data authenticity, security, and traceability [1]

Core Viewpoint - The company, MediWecare (02159.HK), has signed a non-binding memorandum of understanding with a potential seller regarding the acquisition of 100% equity in Hong Kong Huanyu Medical Technology Development Co., Ltd. and its subsidiaries, which are collectively referred to as the "Target Group" [1] Group 1: Acquisition Details - The Target Group primarily provides artificial intelligence technology to global pharmaceutical and medical device companies [1] - The acquisition aims to enhance pharmaceutical research and physician training through innovative AI medical specialty models [1] - The Target Group utilizes Web3 core blockchain technology to ensure data authenticity, security, and traceability [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Mediwelcome Healthcare Management & Technology Inc. 麥迪衛康健康醫療管理科技股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2159） 內幕消息 關於潛在收購事項之諒解備忘錄 本 公 告 乃 由 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司，統 稱「本集團」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（「上市規則」）第 13.09條及香港法例第571章證券及期貨條例第XIVA部 項 下 內 幕 消 息 條 文（定 義 見 上 市 規 則）作 出。 諒解備忘錄僅反映各訂約方對潛在收購事項之初步共識，除上文所載有關排他期、 盡 職 審 查 和 終 止 的 條 款，以 及 有 關（其 中 包 括 ...